Egrifta Replacement and Sleep Disordered Breathing

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Egrifta Replacement and Sleep Disordered Breathing

Official Title

Egrifta Replacement and Sleep Disordered Breathing

Brief Summary

      Sleep-disordered breathing is characterized primarily by partial or total upper airway
      obstruction during sleep. The most common form of sleep-disordered breathing is obstructive
      sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of sleep
      state. The major risk factors associated with the development of sleep apnea are obesity and
      male sex. The investigators have also found a high prevalence of OSA in HIV infected men and
      women, particularly among those with central lipohypertrophy, which is a common finding in
      HIV-infected persons receiving antiretroviral therapy. Currently, our overall hypothesis is
      that visceral adiposity, as seen in HIV-infected persons with central lipohypertrophy, alters
      both mechanical properties and compensatory neuromuscular responses leading to upper airway
      obstruction. Based on our most recent findings in the non-HIV population, the investigators
      demonstrate that obesity is associated with elevations in the upper airway load (passive
      Pcrit) that are counterbalanced by compensatory upper airway neural responses. Moreover, the
      investigators have found that female sex, peripheral adiposity, and younger age are
      associated with increased compensatory neuromuscular responses, while male sex, central
      adiposity, and older age are associated with blunted compensatory responses. The loss of the
      compensatory neuromuscular responses leads to obstructive sleep apnea. Among HIV-infected
      patients with central lipohypertrophy, tesamorelin (Egrifta), a growth hormone releasing
      hormone (GHRH) analogue, is approved for the reduction of visceral adipose tissue. The
      investigators hypothesize that tesamorelin therapy will reverse both the mechanical and
      neurocompensatory alterations associated with increased central obesity. In this project the
      investigators will determine whether tesamorelin affects sleep apnea severity and
      compensatory neuromuscular responses of the upper airway on sleep and breathing in men and
      women with HIV infection. The proposed studies are designed to elucidate the pathophysiologic
      basis for the development of obstructive sleep apnea in this population. The studies also
      provide insights into the neurohumoral regulation of upper airway function, and potentially
      new approaches to the treatment for sleep-disordered breathing.
    



Study Type

Observational


Primary Outcome

Changes in Sleep Apnea Severity

Secondary Outcome

 Changes in Body Composition

Condition

Lipodystrophy

Intervention

Tesamorelin (Egrifta)

Study Arms / Comparison Groups

 HIV and Lipodystrophy
Description:  The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

May 2012


Primary Completion Date

January 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Consenting adult with documented HIV-infection, ages 18 - 75 years old

          2. Central lipohypertrophy as determined by a clinician

          3. Not currently on Egrifta (tesamorelin) therapy.

        Exclusion Criteria:

          1. Unstable cardiovascular disease (decompensated CHF, myocardial infarction in past 3
             months, revascularization procedure in past 3 months, and unstable arrhythmias);

          2. Uncontrolled hypertension (BP > 190/110);

          3. Presence of cor pulmonale

          4. History of end stage renal disease (on dialysis);

          5. History of end stage liver disease ( e.g. jaundice, ascites, history of recurrent
             gastrointestinal bleeding, transjugular intrahepatic portosystemic shunt (TIPS) ;

          6. Bleeding disorders or coumadin use;

          7. Tracheostomy

          8. Active malignancy

          9. Pregnancy and/or nursing mother -
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Philip L Smith, M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01788462

Organization ID

NA_00074675


Responsible Party

Principal Investigator

Study Sponsor

Johns Hopkins University


Study Sponsor

Philip L Smith, M.D., Principal Investigator, Johns Hopkins University


Verification Date

March 2017